ES2325722B1 - USE OF SUBSTITUTED PIRAZOLINE COMPOUNDS FOR THE PREPARATION OF MEDICINES FOR THE TREATMENT OF METABOLIC SYNDROME. - Google Patents

Abstract

Use of substituted pyrazoline compounds for the preparation of medications for the treatment of the syndrome metabolic.

The present invention relates to the use of substituted pyrazoline compounds for the manufacture of a medication for the treatment of metabolic syndrome.

Description

Use of substituted pyrazoline compounds for the preparation of medications for the treatment of the syndrome metabolic.

Field of the Invention

The present invention relates to the use of substituted pyrazoline compounds, for the manufacture of a medication for the treatment of metabolic syndrome.

Background of the invention

The metabolic syndrome is a very disease widespread, particularly in the United States and Europe. Based on the study data from 1988 to 1994 and the data from the 2000 census, the American Center for Disease Control and Prevention estimates that 47 million people in the US have the metabolic syndrome. Thus, there is an urgent need for a therapy. Effective for metabolic syndrome.

Description of the invention

Therefore, it is an object of the present invention provide medications that are suitable for the Metabolic syndrome treatment.

Said object has been achieved using compounds of substituted pyrazoline of general formula I given below, N-oxides, stereoisomers, corresponding salts and corresponding solvates thereof.

Therefore, in one of its aspects this invention relates to the use of at least one pyrazoline compound substituted of general formula I,

one

in the that

R 1 represents a phenyl group optionally at least monosubstituted,

R2 represents a phenyl group optionally at least monosubstituted,

R 3 represents a cycloaliphatic group saturated or unsaturated, optionally at least monosubstituted, which optionally contains at least one heteroatom as a member of ring, which can be condensed with a cyclic, mono or polycyclic, optionally at least monosubstituted, or R3 represents an aryl or heteroaryl group optionally at least monosubstituted, which may be condensed with a cyclic system, mono or polycyclic, optionally at least monosubstituted, or R 3 represents a moiety -NR 4 R 5,

R 4 and R 5, identical or different, they represent a hydrogen atom, an aliphatic radical, not branched or branched, saturated or unsaturated, optionally at less monosubstituted, a saturated cycloaliphatic group or unsaturated, optionally at least monosubstituted, containing optionally at least one heteroatom as a ring member, which it can be condensed with a cyclic, mono or polycyclic system, optionally at least monosubstituted, or an aryl group or optionally at least monosubstituted heteroaryl, which may be condensed with a cyclic, mono or polycyclic system, optionally at least monosubstituted and / or linked through a linear or branched alkylene group, a moiety -SO2 -R6, or a moiety -NR 7 R 8,

R 6 represents an aliphatic, linear or branched, saturated or unsaturated, optionally at least monosubstituted, a saturated or unsaturated cycloaliphatic group, optionally at least monosubstituted, which optionally contains at least one heteroatom as a ring member, which may be condensed with a cyclic, mono or polycyclic system, or a group aryl or heteroaryl optionally at least monosubstituted, which can be condensed with a cyclic, mono or polycyclic system and / or linked through a linear or branched alkylene group,

R 7 and R 8, identical or different, they represent a hydrogen atom, an aliphatic radical, not branched or branched, saturated or unsaturated, optionally at less monosubstituted, a saturated cycloaliphatic group or unsaturated, optionally at least monosubstituted, containing optionally at least one heteroatom as a ring member, which may be condensed with a

cyclic, mono or polycyclic system, optionally at least monosubstituted, or an aryl group or optionally at least monosubstituted heteroaryl, which may be condensed with a cyclic, mono or polycyclic system, optionally at least monosubstituted and / or linked through a linear or branched alkylene group,

optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any mixing ratio, or a corresponding N-oxide of the themselves, or a corresponding salt thereof, or a solvate corresponding thereof,

for the manufacture of a medicine the Metabolic syndrome treatment.

The metabolic syndrome and its definitions are described in detail by Eckel et al , The Lancet, Vol 365 (2005), 1415-1428, included herein as a reference. One of the respective definitions was established by WHO in 1998 (as described in Alberti et al ., Diabet. Med. 1998, 15, pages 539-53, the respective descriptions are incorporated by reference to this document and are part of the description). The other more widely accepted definition of metabolic syndrome was established by the Adult Treatment Panel (ATP III) of the US National Cholesterol Education Program (NCEP) in 2001, as described in JAMA 2001; 285; 2486-97, the respective descriptions are incorporated by reference to this document and are part of the description.

The metabolic syndrome is characterized by a interaction of several physiological parameters such as triglycerides, lipids, blood pressure, glucose levels and insulin levels

Even though obesity plays a role critical in the development of metabolic syndrome, many of its aspects are independent of weight, especially some lipid parameters. Especially the positive influence on independent aspects of the weight of the metabolic syndrome (see for example, Pagotto and Pasquali, The Lancet, Vol. 365 (2005), 1363, 1364, included herein as a reference) as some blood parameters, especially lipid parameters It is one of the main and surprising advantages of substituted piperazine compounds used according to the invention.

As pyrazoline compounds as defined in this document also have an effect beneficial in the proportion of low density lipoproteins (LDL) with respect to high density lipoproteins (HDL), is that is, they decrease LDL levels and / or raise HDL levels; They are also useful as a coating material or as a material of stent co-covering to prevent restenosis

The term "treatment" as used in the This application covers prevention, reduction and / or complete disease recovery. That term also includes the prevention, diminution and / or complete recovery of one or more of The symptoms associated with the disease.

A mono or polycyclic cyclic system according to the present invention means a cyclic hydrocarbon mono system or polycyclic that can be saturated, unsaturated or aromatic. If he cyclic system is polycyclic, each of the different rings it can show a different degree of saturation, that is, it can be saturated, unsaturated or aromatic. Optionally each of the mono or bicyclic cyclic system rings may contain one or more, preferably 1, 2 or 3, heteroatom (s) as ring member (s), which may be identical or different and which can preferably be selected from the group consisting at N, O and S. Preferably, the polycyclic cyclic system can Understand two rings that are condensed. The rings of mono or polycyclic cyclic system are preferably 5 or 6 members.

The term "condensate" according to the present invention means that a ring or cyclic system is attached to another ring or cyclic system, in which the terms "voided" or "anelated" are also used by experts  in the art to designate this kind of union.

If one or more of the waste R 3 -R 8 represents or comprises a group saturated or unsaturated cycloaliphatic, which optionally contains the minus a heteroatom as a ring member, which is substituted by one or more, for example, 1, 2, 3 or 4, substituents, unless otherwise defined, each of the substituents can be independently selected from the group consisting of hydroxyl, fluorine, chlorine, bromine, C 1-6 alkoxy branched or unbranched, C 1-6 alkyl branched or unbranched, perfluoroalkoxy C 1-4 branched or unbranched, C 1-4 perfluoroalkyl branched or unbranched branched, oxo, amino, carboxyl, amido, cyano, nitro, -SO2 NH2, -CO-alkyl C 1-4, -SO-alkyl C 1-4, -SO 2 -alkyl C_ {1-4}, -NH-SO2 -alkyl C 1-4, in which the alkyl C_ {1-4} can, in each case, be branched or not branched, and a phenyl group, more preferably selected from the group consisting of hydroxyl, F, Cl, Br, methyl, ethyl, methoxy, ethoxy, oxo, CF 3 and a phenyl group.

If one or more of the waste R 3 -R 8 represents or comprises a group cycloaliphatic, which contains one or more heteroatoms as members of ring, unless otherwise defined, each of these heteroatoms can preferably be selected from the group that consists of N, O and S. Preferably, a cycloaliphatic group can contain 1, 2 or 3 selected heteroatoms regardless of the group consisting of N, O and S as members ring

Saturated or unsaturated cycloaliphatic groups, optionally at least monosubstituted, which optionally contain at least one heteroatom as a ring member can be selected preferably from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, pyrrolidinyl, piperidinyl, piperazinyl, homo-piperazinyl and morpholinyl.

If one or more of the waste R 3 -R 8 comprises a mono or cyclic system polycyclic, which is substituted by one or more, for example, 1, 2, 3, 4 or 5 substituents, unless otherwise defined, each one of the substituents can be selected independently of the  group consisting of hydroxyl, fluorine, chlorine, bromine, alkoxy C 1-6 branched or unbranched, alkyl C 1-6 branched or unbranched, C 1-4 perfluoroalkoxy branched or unbranched branched, branched C 1-4 perfluoroalkyl or unbranched, amino, carboxyl, oxo, amido, cyano, nitro, -SO2 NH2, -CO-alkyl C 1-4, -SO-alkyl C 1-4, -SO 2 -alkyl C_ {1-4}, -NH-SO2 -alkyl C 1-4, in which the alkyl C_ {1-4} can, in each case, be branched or not branched, and a phenyl group, more preferably selected from the group consisting of hydroxyl, F, Cl, Br, methyl, ethyl, methoxy, ethoxy, CF 3, oxo and a phenyl group.

If one or more of the waste R 1 -R 8 represents or comprises a group aryl, including a phenyl group, which is substituted by one or more, for example, 1, 2, 3, 4 or 5 substituents, unless define otherwise, each of the substituents can independently selected from the group consisting of an atom halogen (for example, F, Cl, Br, I), an alkyl group C 1-6 linear or branched, an alkoxy group Linear or branched C 1-6, a formyl group, a hydroxyl group, a trifluoromethyl group, a group trifluoromethoxy, a -CO-alkyl group C 1-6, a cyano group, a nitro group, a group carboxyl, a -CO-O-alkyl group C_ {1-6}, a remainder -CO-NR A R B, a remainder -CO-NH-NR C R D, a -SH, a -S-C 1-6 alkyl group, a -SO-C 1-6 alkyl group, a -SO 2 -C 1-6 alkyl group, a group - (alkylene C 1-6) - S-alkyl C 1-6, a group - (alkylene C 1-6) - SO-alkyl C 1-6, a group - (alkylene C 1-6) - SO 2 -alkyl C_ {1-6}, a residue -NH2, an NHR 'residue or a remainder NR'R '', in which R 'and R' 'independently represent a linear or branched C 1-6 alkyl group, a C 1-6 alkyl group substituted by one or more hydroxyl groups and a group - (alkylene C 1-6) - NR E R F,

in which R A, R B, identical or different, they represent hydrogen or an alkyl group C 1-6, or R A and R B together with the atom of nitrogen that forms a bridge form a saturated cyclic system, mono or bicyclic, 3-10 membered heterocyclic, which may optionally be at least monosubstituted by one or more C 1-6 alkyl groups, identical or different, and / or that may contain at least one heteroatom additional selected from the group consisting of nitrogen, oxygen and sulfur as a ring member,

R C, R D, identical or different, they represent a hydrogen atom, an alkyl group C_ {1-6}, a group -CO-O-alkyl C 1-6, a cycloalkyl group C 3-8, a group (alkylene C 1-6) - cycloalkyl C 3-8, a group (alkylene C 1-6) -O-alkyl C 1-6 or an alkyl group C_ {1-6} substituted with one or more groups hydroxyl, or R C, R D together with the nitrogen atom that bridges form a saturated cyclic system, mono or bicyclic, 3-10 membered heterocyclic, which they may be optionally at least monosubstituted by one or more substituents independently selected from the group that consists of C 1-6 alkyl group, a group -CO-C 1-6 alkyl, a -CO-O-alkyl C_ {1-6}, a group -CO-NH-alkyl C_ {1-6}, a group -CS-NH-alkyl C 1-6, an oxo group, an alkyl group C 1-6 substituted with one or more hydroxyl groups, a group (alkylene C 1-6) - O-alkyl C 1-6 and a group -CO-NH2 and / or that may contain at least one additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur as a ring member, and

in which R E, R F, identical or different, they represent hydrogen or an alkyl group C 1-6, or R E and R F together with the atom of nitrogen that forms a bridge form a saturated cyclic system, mono or bicyclic, 3-10 membered heterocyclic, which may optionally be at least monosubstituted by one or more, identical or different alkyl groups C_ {1-6} and / or that may contain at least one additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur as a ring member.

Preferred aryl groups, which may be optionally at least monosubstituted, they are phenyl and naphthyl.

If one or more of the waste R 3 -R 8 represents or comprises a group heteroaryl, which is substituted by one or more, for example, 1, 2, 3, 4 or 5 substituents, unless otherwise defined, each of the substituents can be independently selected from group consisting of a halogen atom (for example, F, Cl, Br, I), a linear or branched C 1-6 alkyl group, a linear or branched C 1-6 alkoxy group, a formyl group, a hydroxyl group, a trifluoromethyl group, a trifluoromethoxy group, a -CO-alkyl group C 1-6, a cyano group, a carboxyl group, a -CO-O-alkyl group C_ {1-6}, a remainder -CO-NR A R B, a remainder -CO-NH-NR C R D, a group -S-C 1-6 alkyl, a group -SO-C 1-6 alkyl, a group -SO2 -C 1-6 alkyl, a group - (alkylene C 1-6) - S-alkyl C 1-6, a group - (alkylene C 1-6) - SO-alkyl C 1-6, a group - (alkylene C 1-6) - SO 2 -alkyl C 1-6, an alkyl group C 1-6 substituted by one or more hydroxyl groups and a group - (C 1-6 alkylene) -NR E R F,

in which R A, R B, identical or different, they represent hydrogen or an alkyl group C 1-6, or R A and R B together with the atom of nitrogen that forms a bridge form a saturated cyclic system, mono or bicyclic, 3-10 membered heterocyclic, which may optionally be at least monosubstituted by one or more C 1-6 alkyl groups, identical or different, and / or that may contain at least one heteroatom additional selected from the group consisting of nitrogen, oxygen and sulfur as a member of the ring,

R C, R D, identical or different, they represent a hydrogen atom, an alkyl group C_ {1-6}, a group -CO-O-alkyl C 1-6, a cycloalkyl group C 3-8, a group (alkylene C 1-6) - cycloalkyl C 3-8, a group (alkylene C 1-6) - O-alkyl C 1-6 or an alkyl group C_ {1-6} substituted with one or more groups hydroxyl, or R C, R D together with the nitrogen atom that bridges form a saturated cyclic system, mono or bicyclic, 3-10 membered heterocyclic, which they may be optionally at least monosubstituted by one or more substituents independently selected from the group that consists of C 1-6 alkyl group, a group -CO-C 1-6 alkyl, a group -CO-O- C 1-6 alkyl, a group -CO-NH- C 1-6 alkyl, a group -CS-NH- C 1-6 alkyl, a group oxo, a C 1-6 alkyl group substituted with one or more hydroxyl groups, a group (alkylene C 1-6) - O-alkyl C 1-6 and a -CO-NH 2 and / or that they may contain at least one additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur as a member of ring, and

in which R E, R F, identical or different, they represent hydrogen or an alkyl group C 1-6, or R E and R F together with the atom of nitrogen that forms a bridge form a saturated cyclic system, mono or bicyclic, 3-10 membered heterocyclic, which may optionally be at least monosubstituted by one or more, identical or different alkyl groups C_ {1-6} and / or that may contain at least one additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur as a ring member,

Heteroatoms, which are present as ring members in the heteroaryl radical, may, unless otherwise defined, independently selected from the group It consists of nitrogen, oxygen and sulfur. Preferably a heteroaryl radical may comprise 1, 2 or 3 heteroatoms independently selected from the group consisting of N, O and S as ring members.

Suitable heteroaryl groups, which may be optionally at least monosubstituted, can be selected preferably from the group consisting of thienyl, furyl, pyrrolyl, pyridinyl, imidazolyl, pyrimidinyl, pyrazinyl, indolyl, quinolinyl, isoquinolinyl, benzo [1,2,5] -thiodiazolyl, benzo [b] thiophenyl, benzo [b] furanyl, imidazo [2,1-b] thiazolyl, triazolyl, and pyrazolyl, more preferably selected from the group that consists of thienyl, benzo [1,2,5] -thiodiazolyl, benzo [b] thiophenyl, imidazo [2,1-b] thiazolyl, triazolyl and pyrazolyl

If one or more of the waste R 4 -R 8 represents or comprises a group linear or branched aliphatic, saturated or unsaturated such as a alkyl group, which is substituted by one or more, for example, 1, 2, 3, 4 or 5 substituents, unless otherwise defined, each  one of the substituents can be independently selected from the group consisting of hydroxyl, fluorine, chlorine, bromine, alkoxy C 1-4 branched or unbranched, C 1-4 perfluoroalkoxy branched or unbranched branched, branched C 1-4 perfluoroalkyl or unbranched, amino, carboxyl, amide, cyano, nitro, -SO2 NH2, -CO-alkyl C 1-4, -SO-alkyl C 1-4, -SO 2 -alkyl C_ {1-4}, -NH-SO2 -alkyl C 1-4, in which the alkyl C_ {1-4} can, in each case, be branched or not branched, and a phenyl group, more preferably selected from the group consisting of hydroxyl, F, Cl, Br, methoxy, ethoxy, CF 3 and a phenyl group.

Linear or branched aliphatic groups, saturated or unsaturated, preferred, which may be substituted by one or more substituents, they can preferably be selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, vinyl, ethynyl,  Propenyl, propynyl, butenyl and butynyl.

If any of the waste R 4 -R 8 represents or comprises a group linear or branched alkylene, said alkylene group can preferably selected from the group consisting of methylene - (CH 2) -, ethylene - (CH 2 -CH 2) -, n-propylene - (CH 2 -CH 2 -CH 2) - or iso-propylene - (- C (CH 3) 2) -.

The use of the compounds of Produced substituted pyrazoline of general formula I provided previously, in which

R 1 represents a phenyl group optionally at least monosubstituted,

R2 represents a phenyl group optionally at least monosubstituted,

R 3 represents a cycloaliphatic group saturated or unsaturated, optionally at least monosubstituted, which optionally contains at least one heteroatom as a member of ring, which can be condensed with a cyclic, mono or polycyclic, optionally at least monosubstituted, or R3 represents an aryl or heteroaryl group optionally at least monosubstituted, which may be condensed with a cyclic system, mono or polycyclic, optionally at least monosubstituted, or R 3 represents a moiety -NR 4 R 5,

R 4 and R 5, identical or different, they represent a hydrogen atom, an aliphatic radical, not branched or branched, saturated or unsaturated, optionally at less monosubstituted, a saturated cycloaliphatic group or unsaturated, optionally at least monosubstituted, containing optionally at least one heteroatom as a ring member, which it can be condensed with a cyclic, mono or polycyclic system, optionally at least monosubstituted, or an aryl group or optionally at least monosubstituted heteroaryl, which may be condensed with a cyclic, mono or polycyclic system, optionally at least monosubstituted and / or linked through a linear or branched alkylene group, a moiety -SO 2 -R 6, or a moiety -NR 7 R 8,

R 6 represents an aliphatic, linear or branched, saturated or unsaturated, optionally at least monosubstituted, a saturated or unsaturated cycloaliphatic group, optionally at least monosubstituted, which optionally contains at least one heteroatom as a ring member, which may be condensed with a cyclic, mono or polycyclic system, or a group aryl or heteroaryl optionally at least monosubstituted, which can be condensed with a cyclic, mono or polycyclic system and / or linked through a linear or branched alkylene group,

R 7 and R 8, identical or different, they represent a hydrogen atom, an aliphatic radical, not branched or branched, saturated or unsaturated, optionally at less monosubstituted, a saturated cycloaliphatic group or unsaturated, optionally at least monosubstituted, containing optionally at least one heteroatom as a ring member, which it can be condensed with a cyclic, mono or polycyclic system, optionally at least monosubstituted, or an aryl group or optionally at least monosubstituted heteroaryl, which may be condensed with a cyclic, mono or polycyclic system, optionally at least monosubstituted and / or linked through a linear or branched alkylene group,

optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any mixing ratio, or a corresponding N-oxide of the themselves, or a corresponding salt thereof, or a solvate corresponding thereof.

The use of the compounds of Produced substituted pyrazoline of general formula I provided above, in which R 1 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a group linear or branched C 1-6 alkyl, a group linear or branched C 1-6 alkoxy, an atom of halogen, CH2F, CHF2, CF3, CN, OH, NO2, - (C = O) -R ', SH, SR', SOR ', SO_2R', NH_ {2}, NHR ', NR'R' ', - (C = O) -NH2, - (C = O) -NHR 'and - (C = O) -NR'R' ', in the that R 'and R' 'for each substituent independently represent linear or branched C 1-6 alkyl, preferably R 1 represents a phenyl group, which is optionally substituted by one or more selected substituents from the group consisting of methyl, ethyl, F, Cl, Br and CF 3, plus preferably R 1 represents a phenyl group, which is substituted with a chlorine atom in position 4, and R2 -R8 have the meaning given above, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any mixing ratio, or a corresponding N-oxide of the themselves, or a corresponding salt thereof, or a solvate corresponding thereof.

The use of the compounds of Produced substituted pyrazoline of general formula I provided above, in which R2 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a group linear or branched C 1-6 alkyl, a group linear or branched C 1-6 alkoxy, an atom of halogen, CH2F, CHF2, CF3, CN, OH, NO2, - (C = O) -R ', SH, SR', SOR ', SO_2R', NH_ {2}, NHR ', NR'R' ', - (C = O) -NH2, - (C = O) -NHR 'and - (C = O) -NR'R' 'in the that R 'and R' 'for each substituent independently represent linear or branched C 1-6 alkyl, preferably R2 represents a phenyl group, which is optionally substituted by one or more selected substituents from the group consisting of methyl, ethyl, F, Cl, Br and CF 3, plus preferably R2 a phenyl group, which is disubstituted with two chlorine atoms in positions 2 and 4, and R1 and R 3 -R 8 have the meaning given above, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in  any mixing ratio, or a corresponding N-oxide of the themselves, or a corresponding salt thereof, or a solvate corresponding thereof.

Preference is also given to the use of substituted pyrazoline compounds produced of general formula I provided above, in which R 3 represents a group C 3-8 cycloaliphatic, saturated or unsaturated, optionally at least monosubstituted, which optionally contains at least one heteroatom as a ring member, which may be condensed with a cyclic, mono or polycyclic system, optionally at least monosubstituted, or R3 represents a 5 or 6 membered aryl or heteroaryl group, optionally at least monosubstituted, which may be condensed with a cyclic system, mono or polycyclic, optionally at least monosubstituted, or R 3 represents a moiety -NR 4 R 5, preferably R 3 represents a C 3-8 cycloaliphatic group saturated, optionally at least monosubstituted, containing optionally one or more nitrogen atoms as members of ring, which can be condensed with a cyclic, mono or polycyclic, optionally at least monosubstituted, or R3 represents a moiety -NR 4 R 5, more preferably R 3 represents a pyrrolidinyl group, a piperidinyl group or a group piperazinyl, in which each of these groups may be substituted with one or more C 1-6 alkyl groups, or  R 3 represents a moiety -NR 4 R 5 and R 1, R 2 and R 4 -R 8 have the meaning given above, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any mixing ratio, or a corresponding N-oxide of the themselves, or a corresponding salt thereof, or a solvate corresponding thereof.

In addition, the use of the compounds of Produced substituted pyrazoline of general formula I provided above, in which R 4 and R 5, identical or different, they represent a hydrogen atom, aliphatic radical C 1-6, unbranched or branched, saturated or unsaturated, optionally at least monosubstituted, a group C 3-8 saturated cycloaliphatic, optionally at less monosubstituted, optionally containing at least one or more nitrogen atoms as ring members, which may be condensed with a cyclic, mono or polycyclic system, optionally at least monosubstituted, or an aryl group or 5- or 6-membered heteroaryl, optionally at least monosubstituted, which may be condensed with a cyclic system, mono or polycyclic, optionally at least monosubstituted and / or join through a methylene (-CH2 -) or ethylene group (-CH_ {2} -CH_ {2}) -, a remainder -SO 2 -R 6, or a moiety -NR 7 R 8, preferably one of these residues R 4 and R 5 represents one hydrogen atom and the other of these residues R 4 and R 5 represents a C 3-8 cycloaliphatic group, saturated or unsaturated, optionally at least monosubstituted, which optionally contains at least one heteroatom as a member of ring, which can be condensed with a cyclic, mono or polycyclic, optionally at least monosubstituted, or an aryl group or 5 or 6 membered heteroaryl, optionally at least monosubstituted, which may be condensed with a cyclic system, mono or polycyclic, optionally at least monosubstituted, a moiety -SO 2 -R 6, or a moiety -NR 7 R 8, or R 4 and R 5, identical or different, each represent a C 1-6 alkyl group, more preferably one of residues R 4 and R 5 represents a hydrogen atom and the other of these residues R 4 and R 5 represents a group optionally at least monosubstituted pyrrolidinyl, a group optionally at least monosubstituted piperidinyl, a group optionally at least monosubstituted piperazinyl, a group optionally at least monosubstituted triazolyl, a moiety -SO 2 -R 6, or a moiety -NR 7 R 8, or R 4 and R 5, identical or different, represent a group methyl, an ethyl group, an n-propyl group, a isopropyl group, an n-butyl group, a group sec-butyl or a tert-butyl group, and R 1 -R 3 and R 6 -R 8 they have the meaning given above, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any mixing ratio, or an N-oxide corresponding thereof, or a corresponding salt of the themselves, or a corresponding solvate thereof.

The use of the compounds of Produced substituted pyrazoline of general formula I provided above, in which R 6 represents an aliphatic group C 1-6, linear or branched, saturated or unsaturated, optionally at least monosubstituted, a group cycloaliphatic, saturated or unsaturated, optionally at least monosubstituted, optionally containing at least one heteroatom as a ring member, which may be condensed with a system cyclic, mono or polycyclic, or an aryl or heteroaryl group of 5 or 6 members, optionally at least monosubstituted, which may be condensed with a cyclic, mono or polycyclic system and / or attached to through a methylene group (-CH2) or ethylene (-CH 2 -CH 2) -, preferably R 6 represents a C 1-6 alkyl group, a group saturated cycloaliphatic, optionally at least monosubstituted, which it can be condensed with a cyclic, mono or polycyclic system, or a phenyl group, which is optionally substituted with one or more C 1-6 alkyl groups, and R 1 -R 5, R 7 and R 8 have the meaning given above, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any mixing ratio, or an N-oxide corresponding thereof, or a corresponding salt of the themselves, or a corresponding solvate thereof.

In addition, the use of the compounds of Produced substituted pyrazoline of general formula I provided above, in which R 7 and R 8, identical or different, they represent a hydrogen atom, an aliphatic radical C 1-6, unbranched or branched, saturated or unsaturated, optionally at least monosubstituted, a group cycloaliphatic, saturated or unsaturated, optionally at least monosubstituted, optionally containing at least one heteroatom as a ring member, which may be condensed with a system cyclic, mono or polycyclic, optionally at least monosubstituted, or a 5 or 6 membered aryl or heteroaryl group, optionally at less monosubstituted, which may be condensed with a system cyclic, mono or polycyclic, optionally at least monosubstituted and / or linked through a methylene (-CH2 -) or ethylene group (-CH2 -CH2) -, preferably represent a hydrogen atom or an alkyl radical C 1-6, and R 1 -R 6 have the meaning provided above, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any mixing ratio, or an N-oxide corresponding thereof, or a corresponding salt of the themselves, or a corresponding solvate thereof.

Particularly preferred is the use of at least a substituted pyrazoline compound of general formula I, in the that

R 1 represents a phenyl group that is optionally substituted by one or more selected substituents regardless of the group consisting of methyl, ethyl, F, Cl, Br and CF 3,

R2 represents a phenyl group that is optionally substituted by one or more selected substituents regardless of the group consisting of methyl, ethyl, F, Cl, Br and CF 3,

R 3 represents a pyrrolidinyl group, a piperidinyl group or a piperazinyl group, in which each of those groups may be substituted with one or more alkyl groups C 1-6, or R 3 represents a residue-NR 4 R 5 -,

one of the residues R 4 and R 5 represents one hydrogen atom and the other of these residues R 4 and R 5 represents a pyrrolidinyl group optionally at least monosubstituted; a piperidinyl group optionally at least monosubstituted; a piperazinyl group optionally at least monosubstituted; a triazolyl group optionally at least monosubstituted; a moiety -SO 2 -R 6 -; or a remainder -NR 7 R 8 -, or R 4 and R 5, identical or different, represents a methyl group, an ethyl group, a group n-propyl, an isopropyl group, a group n-butyl, a sec-butyl group or a tert-butyl group,

R 6 represents an alkyl group C 1-6; a cycloaliphatic group, saturated, optionally at least monosubstituted, which may be condensed with a cyclic, monocyclic or polycyclic system; or a group phenyl that is optionally substituted with one or more groups C 1-6 alkyl, and

R 7 and R 8, identical or different, represents a hydrogen atom or an alkyl radical C_ {1-6}.

Also, the use of at least one substituted pyrazoline compound of the general formula I, in which

R 1 represents a phenyl group that is optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of alkyl C 1-6 linear or branched, alkoxy C 1-6 linear or branched, F, Cl, Br, I, CH 2 F, CHF 2, CF 3, CN, OH, NO 2, - (C = O) -R ', SH, SR', SOR ', SO_2R', NH_ {2}, NHR ', NR' R '', - (C = O) -NH2, - (C = O) -NHR 'and - (C = O) -NR'R' ', in the that R 'and R' 'each time they appear represent independent a linear C 1-6 alkyl group or branched,

R2 represents a phenyl group that is optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of alkyl C 1-6 linear or branched, alkoxy C 1-6 linear or branched, F, Cl, Br, I, CH 2 F, CHF 2, CF 3, CN, OH, NO 2, - (C = O) -R ', SH, SR', SOR ', SO_2R', NH_ {2}, NHR ', NR'R' ', - (C = O) -NH2, - (C = O) -NHR 'and - (C = O) -NR'R' ', in the that R 'and R' 'each time they appear represent independent a linear C 1-6 alkyl group or branched,

R 3 represents a cycloaliphatic group C_ {3-8} saturated or unsaturated, in which said C 3-8 cycloaliphatic group is substituted optionally with 1, 2, 3 or 4 substituents selected regardless of the group consisting of alkyl C 1-6 linear or branched, alkoxy C 1-6 linear or branched, OH, F, Cl, Br, I, CN, CH 2 F, CHF 2, CF 3 and oxo (= O) and in which said C 3-8 cycloaliphatic group may contain 1, 2 or 3 heteroatoms independently selected from the group that consists of N, O and S as members of the ring, or R3 represents a moiety -NR 4 R 5 -,

R 4 represents a hydrogen atom or a linear or branched C 1-6 alkyl group,

R 5 represents an alkyl group C 1-6 linear or branched; a rest -SO 2 -R 6 -; a cycloaliphatic group C_ {3-8} saturated or unsaturated, in which said C 3-8 cycloaliphatic group is substituted optionally with 1, 2, 3 or 4 substituents selected regardless of the group consisting of alkyl group C 1-6 linear or branched, an alkoxy group C 1-6 linear or branched, OH, F, Cl, Br, I, CN CH 2 F, CHF 2, CF 3 and oxo (= O) and in which said group C 3-8 cycloaliphatic may contain 1, 2 or 3 heteroatoms independently selected from the group that consists of N, O and S as members of the ring, and

R 6 represents a phenyl group that is optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of a group  linear or branched C 1-6 alkyl, a group linear or branched C 1-6 alkoxy, F, Cl, Br, I, CH 2 F, CHF 2, CF 3, CN, OH, NO 2, - (C = O) -R ', SH, SR', SOR ', SO_2R', NH_ {2}, NHR ', NR' R '', - (C = O) -NH2, - (C = O) -NHR 'and - (C = O) -NR'R' ', in the that R 'and R' 'each time they appear represent independent a linear C 1-6 alkyl group or branched.

In addition, the use of al  minus a substituted pyrazoline compound of general formula I, in which

R 1 represents a phenyl group that is optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of methyl, ethyl, F, Cl, Br and CF 3,

R2 represents a phenyl group that is optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of methyl, ethyl, F, Cl, Br and CF 3,

R 3 represents a pyrrolidinyl group, a piperidinyl group or a piperazinyl group, in which each of those groups may be substituted with one or more alkyl groups C 1-6, or R 3 represents a moiety -NR 4 R 5 -,

R 4 represents a hydrogen atom or a linear or branched C 1-6 alkyl group,

R 5 represents an alkyl group C 1-6 linear or branched; a rest -SO 2 -R 6 -; a pyrrolidinyl group; a piperidinyl group; a piperazinyl group; a group homo-piperazinyl; a morpholinyl group; a group triazolyl; in which each of the heterocyclic rings can  be substituted with one or more alkyl groups C_ {1-6}, identical or different, and

R 6 represents a phenyl group that is optionally substituted with one or more alkyl groups C_ {1-6}, which can be identical or different.

In addition, the use of al  minus a substituted pyrazoline compound of general formula I, in which

R 1 represents a phenyl ring, which is monosubstituted with a halogen atom, preferably an atom of chlorine, in position 4,

R2 represents a phenyl ring, which is disubstituted with two halogen atoms, preferably atoms of chlorine, in its position 2 and 4,

R 3 represents a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, a group homo-piperazinyl, a morpholinyl group, or a moiety -NR 4 R 5 -,

R 4 represents a hydrogen atom or a linear or branched C 1-6 alkyl group,

R 5 represents an alkyl group C 1-6 linear or branched; a rest -SO 2 -R 6 -; a pyrrolidinyl group; a piperidinyl group; a piperazinyl group; a group homo-piperazinyl; a morpholinyl group; or a group triazolyl in which each of the heterocyclic rings can be substituted with one or more alkyl groups C_ {1-6}, identical or different, and

R 6 represents a phenyl group that is optionally substituted with one or more alkyl groups C_ {1-6}, which can be identical or different.

In addition, the use is more particularly preferred. of at least one pyrazoline compound selected from the group Constituted by

N-piperidinyl-5- (4-chloro-phenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-1H-pyrazol-3-carboxamide,

[1,2,4] -triazol-4-yl-amide of the acid 5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carboxylic acid,

(4-methyl-piperazin-1-yl) -amide of the acid 5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carboxylic acid,

acid diethylamide 5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carboxylic acid,

[5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-yl] -piperidine-1-yl-methanone Y

N- [5- (4-Chloro-phenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -4-methylphenylsulfonamide,

optionally in the form of one of stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any mixing ratio, or a corresponding N-oxide of the themselves, or a corresponding salt thereof, or a solvate corresponding of same.

Also, the use is more particularly preferred. of one of the following two pyrazoline compounds:

2

in each case optionally fit of a corresponding N-oxide, a corresponding salt, or a corresponding solvate of the same.

It has been found that the compounds of substituted pyrazoline used according to the invention as defined in  This document has a great affinity for the receptors of cannabinnoids, particularly cannabinnoid receptors 1 (CB1), that is they are selective ligands of the receptors (CB1), and act as modulators, that is, antagonists, Inverse agonists or agonists of these receptors.

In addition, these pyrazoline compounds show a relatively weak affinity for the Herg channel, therefore, for these compounds a low risk of prolongation of the QT interval

In summary, the pyrazoline compounds used according to the invention they are distinguished by a wide spectrum of effects beneficial while at the same time show relatively few unwanted effects, that is, effects that do not contribute positive way to or that even interfere with the welfare of patient.

Another aspect of the invention is the use of one or more pyrazoline compounds, as defined herein document, for the manufacture of a medicine for the improvement of cardiovascular and / or metabolic risk factors, such as one or more of the following factors:

Elevated triglycerides, in which levels elevated triglycerides are preferably understood to be> 150 mg / dl,

Low HDL cholesterol, in which the low cholesterol levels of HDL is preferably understood which are <40 mg / dl in men and <50 mg / dl in women,

Hypertension, in which hypertension is understood  preferably that is> 130/85 mmHg,

Fasting impaired glucose, in which the  fasting impaired glycemia is preferably understood which is> 110 mg / dl,

       \ vskip1.000000 \ baselineskip
    

Insulin resistance Dyslipidemia

Another aspect of the invention is the use of one or more pyrazoline compounds, as defined herein document, for the manufacture of a medicine for the treatment of the independent aspects of the weight of the syndrome metabolic.

Another aspect of the invention is a method for improve cardiovascular and / or metabolic risk factors, such as one or more of the following factors:

Elevated triglycerides, in which levels elevated triglycerides are preferably understood to be> 150 mg / dl,

Low HDL cholesterol, in which the low cholesterol levels of HDL is preferably understood which are <40 mg / dl in men and <50 mg / dl in women,

Hypertension, in which hypertension is understood  preferably that is> 130/85 mmHg,

Fasting impaired glucose, in which the  fasting impaired glycemia is preferably understood which is> 110 mg / dl,

       \ vskip1.000000 \ baselineskip
    

Insulin resistance Dyslipidemia

In a subject, preferably a human being.

Another aspect of the invention is a method for treat independent aspects of the weight of the syndrome metabolic.

Pyrazoline compounds of the general formula (I) used according to the invention given above, the stereoisomers, the corresponding N-oxides, salts corresponding thereof, and the corresponding solvates are toxicologically acceptable, and therefore are suitable as pharmaceutically active principles for the preparation of medicines.

The medicament obtained according to the invention can  be in any form suitable for application to patients humans, adults as well as children and can be produced by usual procedures known to those skilled in the art. The composition of the medication may vary depending on the route of administration.

Such medications can be produced by usual procedures known to those skilled in the art, for example, from the index of "Pharmaceutics: The Science of Dosage Forms ", second edition, Aulton, M.E. (ED. Churchill Livingstone, Edinburgh (2002); "Encyclopedia of Pharmaceutical Technology ", second edition, Swarbrick, J. and Boiloan J.C. (Eds.), Marcel Dekker, Inc. New York (2002); "Modern Pharmaceutics ", fourth edition, Banker G.S. and Rhodes C.T. (Eds.) Marcel Dekker, Inc. New York 2002 and "The Theory and Practice of Industrial Pharmacy ", Lachman L., Lieberman H. and Kanig J. (Eds.), Lea & Febiger, Philadelphia (1986). The descriptions respective are incorporated as a reference to this document and They are part of the description.

The medicament obtained according to the present invention can, for example, be administered parenterally in combination with conventional injectable liquid carriers, such as water or suitable alcohols. Conventional pharmaceutical excipients, such as stabilizing agents, solubilizing agents and buffers, may be included in such injectable compositions. These medications can be injected, for example, intramuscularly, intraperitoneally, or intravenously. The medicament obtained according to the present invention can also be administered topically, for example by means of a therapeutic transdermal system (STT), or through a
suppository.

In a preferred embodiment of the present invention, the medicament is suitable for administration via oral.

Suitable forms for oral administration include tablets, dragees, capsules, syrups, gels, juices (oil or water based), chewing gums, aerosols, aqueous or oily suspensions, dry powder forms, preferably in sachets, suitable for reconstitution with water or other suitable liquid medium before its
use.

Other forms suitable for administration orally they are multiparticulate formulations, preferably microcompressed, microparticles, nanoparticles, microgranules or granules, optionally tablets in one tablet, filled in a capsule or suspended in a suitable liquid. Liquids Suitable are known to those skilled in the art.

The medicament obtained according to the invention can  also comprise at least one substituted pyrazoline compound of general formula I given above, at least partially in sustained release form. By incorporating one or more of the substituted pyrazoline compounds of the general formula I given above at least partially or completely in a form of sustained release, it is possible to extend the duration of your effect, providing the beneficial effects of such form of sustained release, for example, the maintenance of optimal therapeutic concentrations in plasma or tissues.

Suitable controlled release formulations, materials and methods for their preparation are known from the prior art, for example, from the "Modified-Release Drug Delivery Technology" index, Rathbone,
MJ Hadgraft, J. and Roberts, MS (Eds.), Marcel Dekker, Inc., New York (2002); "Handbook of Pharmaceutical Controlled Release Technology", Wise, DL (Ed.), Marcel Dekker, Inc. New York, (2000); "Controlled Drug Delivery", Vol, I, Basic Concepts, Bruck, SD (Ed.), CRD Press Inc., Boca Raton (1983) and de Takada, K. and
Yoshikawa, H., "Oral Drug Delivery," Encyclopedia of Controlled Drug Delivery, Matiowitz, E. (Ed.), John Wiley & Sons, Inc., New York (1999), Vol. 2, 728-742; Fix, J., "Oral drug delivery, small intestine and colon", Encyclopedia of Controlled Drug Delivery, Matiowitz, E. (Ed.), John Wiley & Sons, Inc., New York (1999), Vol. 2, 698 -728. The respective descriptions are incorporated by reference to this document and are part of the
description.

If the medicine obtained according to this invention comprises at least one of the pyrazoline compounds substituted of general formula I at least partially in the form of sustained release, such sustained release can be achieved preferably by the application of at least one coating or the provision of a matrix comprising at least one material of sustained release

The sustained release material is preferably based on an optionally modified polymer, insoluble in water, natural, semi-synthetic or synthetic, or a wax or fat or fatty alcohol or fatty acid, natural, semi-synthetic or synthetic or in a mixture of at least two of these components previously mentioned.

The water insoluble polymers used to  produce a sustained release material are preferably a base of an acrylic resin, which is preferably selected from the group of poly (meth) acrylates, particularly of preferred way alkyl ((meth) acrylates (C 1-4)), poly ((meth) acrylates of dialkylamino (C 1-4) - (C 1-4) alkyl) and / or copolymers or mixtures thereof, and very particularly preferred ethyl acrylate copolymers and methyl methacrylate with a monomeric molar ratio of 2: 1 (Eudragit NE30D®), copolymers of ethyl acrylate, methacrylate  methyl and trimethylammonium methacrylate chloride ethyl (with a monomeric molar ratio of 1: 2: 0.1 (Eudragit RS®), copolymers of ethyl acrylate, methyl methacrylate and chloride of ethyl trimethylammonium methacrylate with a 1: 2: 0.2 monomeric molar ratio (Eudragit RL®), or a mixture of at least two of the aforementioned copolymers. These coating materials are commercially available as 30% by weight aqueous latex dispersions, that is, as Eudragit RS30D®, Eudragit NE30D® or Eudragit RL30D®, and also They can be used as such for coating purposes.

In another embodiment, the release material sustained is based on water-insoluble cellulose derivatives, preferably alkylcelluloses, particularly preferred ethyl cellulose or cellulose esters, for example acetate of cellulose. Aqueous ethyl cellulose dispersions are commercially available, for example, under the brands Registered Aquacoat® or Surelease®.

As waxes, fats or natural fatty alcohols,  semi-synthetic or synthetic, sustained release material It can be based on carnauba wax, beeswax, monostearate of glycerol, glycerol monobehenate, dithripalmitoestearate glycerol, microcrystalline wax, cetyl alcohol, alcohol cetyl stearyl or a mixture of at least two of these components.

The aforementioned polymers of sustained release material may also comprise a conventional physiologically acceptable plasticizer, in amounts known to those skilled in the art.

Examples of suitable plasticizers are lipophilic diesters of a dicarboxylic acid C 6 -C 40 aliphatic or aromatic and an alcohol C_ {1} -C_ {8} aliphatic, for example, phthalate of dibutyl, diethyl phthalate, dibutyl sebacate or sebacate diethyl, hydrophilic or lipophilic citric acid esters, by example triethyl citrate, tributyl citrate, citrate acetyltributyl or acetyltriethyl citrate, polyethylene glycols, propylene glycol, glycerol esters, for example, triacetin, Myvacet® (mono and acetylated diglycerides, from C 23 H 44 O 5 to C 25 H 47 O 7), triglycerides medium chain (Miglyol®), oleic acid or mixtures of at least two of said plasticizers.

The aqueous dispersions of Eudragit RS® and optionally Eudragit RL® preferably contain citrate of triethyl The sustained release material may comprise one or more plasticizers in amounts of, for example, 5 to 50% in weight based on the amount of polymer (s) used (s).

The sustained release material also may contain other conventional auxiliary substances known to those skilled in the art, for example, lubricants, colored pigments or surfactants.

Medications according to the present invention they can also comprise an enteric coating, so that Its dissolution depends on the pH value. Because of said coating, the medicine can pass through the stomach without dissolve and the compounds of general formula I are released only in the intestinal tract The enteric coating dissolves preferably at a pH between 5 and 7.5.

The enteric coating can be based on any enteric material known to experts in the technique, for example, of acid copolymers methacrylic / methyl methacrylate with a monomeric molar ratio of 1: 1 (Eudragit L®), methacrylic acid / methacrylate copolymers of methyl with a monomeric molar ratio of 1: 2 (Eudragit S®), methacrylic acid / ethyl acrylate copolymers with a ratio 1: 1 monomeric molar (Eudragit L30D-55®), copolymers of methacrylic acid / methyl acrylate / methacrylate methyl with a monomeric molar ratio of 7: 3: 1 (Eudragit FS®), lacquer, acetate succinates hydroxypropyl methylcellulose acetate acetate phthalates cellulose or a mixture of at least two of these components, which they can also be used optionally in combination with water-insoluble poly (meth) acrylates mentioned, preferably in combination with Eudragit NE30D® and / or  Eudragit RL® and / or Eudragit RS®.

The formulations coatings Pharmaceuticals of the present invention can be applied by conventional procedures known to experts in the technique, for example from Johnson, J.L., "Pharmaceutical tablet coating ", Coatings Technology Handbook (second edition), Satas, D. and Tracton, A.A. (Eds), Marcel Dekker, Inc. New York, (2001), 863-866; Carstensen, T., "Coating Tablets in Advanced Pharmaceutical Solids ", Swarbrick, J. (Ed.), Marcel Dekker, Inc. New York (2001), 455-468; Leopold, C.S., "Coated dosage forms for colon-specific drug delivery ", Pharmaceutical Science & Technology Today, 2 (5), 197-204 (1999), Rhodes, C.T. and Porter, S.C., Coatings, in Encyclopedia of Controlled Drug Delivery. Matiowitz, E. (Ed.), John Wiley & Sons, Inc., New York (1999), Vol. 1, 299-311. The descriptions respective are incorporated as a reference to this document and They are part of this description.

In another embodiment, the medicine obtained according to the present invention, it may contain one or more of the substituted pyrazoline compounds of general formula I not only in the form of sustained release, but also in the form not sustained. By combining with the release form immediate, a high initial dose can be achieved for rapid appearance of the beneficial effect. The slow release of the form sustained release then prevents the effect from diminishing beneficial.

Preferably the medication is designed to an administration once a day, twice a day or three times a day. More preferably the medicament is designed for a administration once a day or twice a day, the most Preferred is a once daily administration.

Another aspect of the present invention relates to to a combination of active ingredients that include component (A) one or more of the pyrazoline compounds substituted as defined herein and as component (B) an agent selected from the group consisting of antihypertensive agents, agents to treat resistance to Insulin and agents to treat dyslipidemia.

Suitable antihypertensive agents, the agents for treating insulin resistance and agents for treat dyslipidemia as well as their doses are well known by experts in the art.

Antihypertensive agents can preferably selected from the group consisting of hydrochlorothiazide, Furosemide, Triamterene, Triamterene / hydrochlorothiazide, Spironolactone, Eplerenone, Amlodipine, Nifedipine, Diltiazem, Verapamil, Atorvastatin / amlodipine, Enalapril, Lisinoprile, Ramiprile, Lisinoprile / hydrochlorothiazide, Benazepril / amlodipine, Losartan, Valsartan, Irbesartan, Cilexetil of aandesartan, Olmesartan, Losartan / hydrochlorothiazide, Valsartan / hydrochlorothiazide, HCT / CoDiovan / Cotareg, Atenolol, Metoprolol Tartrate, Succinate of metoprolol and carvedilol. Agents to treat resistance insulin can preferably be selected from the group that Consists of Metformin, Sustained Release Metformin, Pioglitazone, Rosiglitazone and Metformin / Rosiglitazone. The agents to treat dyslipidemia, they can preferably be selected from the group consisting of Colesevelam, Cholestyramine, Clofibrate, Fenofibrate, Fulcro / Secalip, Bezafibrate, Gemfibrozil, Ciprofibrate, Niacin, Atorvastatin, Fluvastatin, Lovastatin, Pravastatin, Rosuvastatin, Simvastatin, Ezetimibe, Lovastatin / niacin, Atorvastatin / amlodipine and Simvastatin / ezetimibe

The substituted pyrazoline compounds according to the invention can, for example, be obtained by the following procedure, according to which at least one compound of benzaldehyde of general formula II

       \ vskip1.000000 \ baselineskip
    

       \ vskip1.000000 \ baselineskip
    

       \ vskip1.000000 \ baselineskip
    

3

       \ vskip1.000000 \ baselineskip
    

       \ vskip1.000000 \ baselineskip
    

       \ vskip1.000000 \ baselineskip
    

in which R1 has the meaning given above, is reacted with a compound general formula pyruvate (III)

       \ vskip1.000000 \ baselineskip
    

       \ vskip1.000000 \ baselineskip
    

4

       \ vskip1.000000 \ baselineskip
    

       \ vskip1.000000 \ baselineskip
    

in which G represents an OR group where R is a linear C 1-6 alkyl radical or branched, preferably an ethyl radical, or G represents a group O - K with K being a cation, preferably a cation monovalent, more preferably an alkali metal cation, even more preferably a sodium cation, to give a compound of General Formula (IV)

       \ vskip1.000000 \ baselineskip
    

       \ vskip1.000000 \ baselineskip
    

5

       \ newpage
    

in which R1 has the meaning given above, which is optionally isolated and / or optionally purifies, and that is reacted with a general formula phenylhydrazine (V)

       \ vskip1.000000 \ baselineskip
    

       \ vskip1.000000 \ baselineskip
    

6

       \ vskip1.000000 \ baselineskip
    

       \ vskip1.000000 \ baselineskip
    

or a corresponding salt of same, in which R2 has the meaning given above, in an inert atmosphere to give a compound of general formula (SAW)

       \ vskip1.000000 \ baselineskip
    

7

       \ vskip1.000000 \ baselineskip
    

in which R1 and R2 have the meaning given above, which is optionally isolated and / or optionally purified, and optionally transferred in a inert atmosphere in a compound of general formula (VII)

       \ vskip1.000000 \ baselineskip
    

8

       \ vskip1.000000 \ baselineskip
    

in which the R 1 substituents and R2 have the meaning given above and A represents a leaving group, through the reaction with an activating agent,  said compound being optionally isolated and / or purified optionally, and at least one compound of general formula (VI) is reacts with a compound of the general formula R3H, in the that R 3 represents a -NR 4 R 5 - moiety, in which R 4 and R 5 have the meaning given above to give a substituted pyrazoline compound of general formula I, in the that R 3 represents a remainder -NR 4 R 5 -,

and / or at least one compound of the general formula (VII) is reacted with a compound of general formula R 3 H, in which R 3 has the meaning given above to give a compound of general formula (I) given above, which is optionally isolated and / or optionally purified.

The process is also illustrated in scheme 1 given below:

       \ vskip1.000000 \ baselineskip
    

Scheme I

       \ vskip1.000000 \ baselineskip
    

9

       \ vskip1.000000 \ baselineskip
    

The reaction of a benzaldehyde compound of general formula II with a pyruvate compound of general formula III is preferably carried out in the presence of at least one base, more preferably in the presence of a metal hydroxide alkali such as sodium hydroxide or potassium hydroxide or a alkali metal methoxide such as sodium methoxide, are described for example in Synthetic communications, 26 (11), 2229-33, (1996). The respective description is incorporates as reference to this document and is part of the description. Preferably sodium pyruvate can be used as the pyruvate compound Preferably said reaction is carried out. in a protic reaction medium such as an alkyl alcohol C 1-4 or mixtures thereof. They can also mixtures of such alcohols with water are used, for example, ethanol / water

The reaction temperature as well as the Reaction duration may vary over a wide range. The Preferred reaction temperatures range from -10 ° C to boiling point of the reaction medium. Reaction times suitable may vary for example from several minutes to several hours.

It is also preferred that the reaction of the benzaldehyde compound of general formula II with a compound Pyruvate of general formula III is carried out under conditions acid catalyzed, more preferably by putting the mixture at reflux in dichloromethane in the presence of trifluoromethanesulfonate of copper (II) as described, for example, in Synlett, (1), 147-149, 2001. The description respective is incorporated as a reference to this document and It is part of the description.

The reaction of the compound of the general formula (IV) with an optionally substituted phenylhydrazine of the formula general (V) is preferably carried out in a reaction medium suitable such as C 1-4 alcohols - or ethers such as dioxane or tetrahydrofuran or mixtures of at least two of these compounds mentioned above. Also preferably, said reaction can be carried out in the presence of an acid, in which the acid can be organic, such as acetic and / or inorganic acid such as hydrochloric acid. In addition, the reaction can also carried out in the presence of a base such as piperidine, piperazine, sodium hydroxide, potassium hydroxide, sodium methoxide or sodium ethoxide, or a mixture of at least two of these may be used bases.

The reaction temperature as well as the duration of the reaction may vary over a wide range. The suitable reaction temperatures vary from temperature ambient, that is, approximately 25 ° C to the point of boiling of the reaction medium. Adequate reaction times they can vary for example from several minutes to several hours.

The carboxylic group of the compound of formula general (VI) can be activated by additional reactions by introduction of a suitable leaving group according to the methods Conventionals well known to those skilled in the art. Preferably, the compounds of general formula (VI) are transferred into an acid chloride, an acid anhydride, a mixed anhydride, a C 1-4 alkyl ester a activated ester such as p-nitrophenyl ester. Others Well known methods for acid activation include the activation with N, N-dicyclohexylcarbodiimide or hexafluoro phosphate benzotriazol-N-oxotris (dimethylamino) phosphonium (BOP)).

If said activated compound of general formula (VII) is an acid chloride, preferably prepared by the reaction of the corresponding acid of general formula (VI) with thionyl chloride, or oxalyl chloride, wherein said agent Chlorination is also used as the solvent. Too preferably an additional solvent can be used. The Suitable solvents include hydrocarbons such as benzene, toluene or xylene, halogenated hydrocarbons such as dichloromethane, chloroform, or carbon tetrachloride, ethers such as diethyl ether, dioxane, tetrahydrofuran, or dimethoxyethane. You can use the mixtures of two or more solvents of one class or two or more solvents of different kinds. Reaction temperatures Preferred range from 0 ° C to the boiling point of solvents and reaction times from several minutes to several hours.

If said activated compound of general formula (VII) is a mixed anhydride, said anhydride can be prepared preferably, for example, by reaction of the corresponding acid of general formula (VI) with ethyl chloroformate in presence of a base such as triethylamine or pyridine, in a suitable solvent.

The reaction of general formula (VII) with a compound of general formula HR3 to give compounds of general formula I, in which R 3 represents a moiety -NR 4 R 5 is preferably carried out in the presence of a base such as triethylamine in a reaction medium such as methylene chloride The temperature is preferably in the range from 0 ° C to the melting point of the reaction medium. The reaction time may vary over a wide range, by example from several hours to several days.

The reaction of the general formula (VII) with a compound of the general formula HR 3 to give compounds of the general formula I, wherein R 3 represents a cycloaliphatic group optionally containing at least one heteroatom as a ring member , optionally at least monosubstituted, saturated or unsaturated, which may be condensed with an optionally monosubstituted cyclic, monocyclic or polycyclic system, or an optionally at least monosubstituted aryl or heteroaryl group, which may be condensed with a cyclic, monocyclic or polycyclic system optionally at Less monosubstituted can be carried out according to conventional methods well known to those skilled in the art, for example from Pascual, A., J. Prakt Chem., 1999, 341 (7), 695-700; Lin, S. et al ., Heterocycles, 2001, 55 (2), 265-277; Rao, P. et al ., J. Org. Chem., 2000, 65 (22), 7323-7344, Pearson DE and Buehler, CA, Synthesis, 1972, 533-542 and bibliography cited therein. The respective descriptions are incorporated by reference to this document and are part of the description.

Preferably said reaction is carried out. in the presence of a Lewis acid, which is selected preferably from the group consisting of FeCl 3, ZnCl 2 and AlCl 3, in a suitable reaction medium such as toluene, benzene, tetrahydrofuran or the like. The temperature is preferably in the range of 0 ° C to the melting point of the reaction medium, more preferably from 15 to 25 ° C. The time of reaction may vary over a wide range, for example, from Several minutes to several hours.

The reactions mentioned above that assume the synthesis of a ring of 4,5-dihydro-pyrazole or the reaction of a compound comprising said ring are carried out preferably under an inert atmosphere, preferably under a nitrogen or argon atmosphere, to prevent oxidation of the system cyclic.

During the processes described above, protection of sensitive groups may be necessary and / or desirable or of the reagents. The introduction of protective groups conventional as well as its elimination can be done by methods well known to those skilled in the art.

If the substituted pyrazoline compounds of general formula I are obtained in the form of a mixture of stereoisomers, particularly enantiomers or diastereomers, said mixtures can be separated by usual procedures known to those skilled in the art, for example, methods Chromatographic or crystallization with chiral reagents. It is also possible to obtain pure stereoisomers through synthesis Stereoselective

Salts of compounds of substituted pyrazoline of general formula I used according to invention and stereoisomers thereof, by a process in which  at least one compound of general formula I having at least one basic group is reacted with at least one inorganic acid and / or organic, preferably in the presence of a reaction medium suitable. Suitable reaction media include, for example, any of those provided above. Inorganic acids  Suitable include hydrochloric acid, hydrobromic acid, acid phosphoric, sulfuric acid, nitric acid, organic acids Suitable are, for example, citric acid, maleic acid, acid fumaric, tartaric acid, or derivatives thereof, acid p-toluenesulfonic acid, methanesulfonic acid or acid camphorsulfonic.

Salts of substituted pyrazoline compounds of general formula I used according to the invention and stereoisomers thereof can also be prepared by a method in which at least one compound of general formula I having at least one acidic group is reacted with one or more suitable bases, preferably in the presence of a suitable reaction medium. Suitable bases are, for example, hydroxides, carbonates or alkoxides, which include suitable cations, derived for example from alkali metals, alkaline earth metals or organic cations, for example [NH_n_R_ {4-n}] + , where n is 0, 1, 2, 3 or 4 and R represents a branched or unbranched C 1-4 alkyl radical. Suitable reaction media are, for example, any of those given above.
mind.

You can also get solvates, preferably hydrates, of the pyrazoline compounds substitutes of general formula I used according to the invention, of the corresponding stereoisomers, of the corresponding N-oxides or of the corresponding salts thereof by usual procedures known to experts in the technique.

Compounds of substituted pyrazoline of general formula I, comprising rings, saturated, unsaturated or aromatic containing an atom  of nitrogen in the form of its N-oxides by well methods known to those skilled in the art.

Those skilled in the art will understand that the term substituted pyrazoline compounds as used herein is understood to encompass derivatives such as ethers, esters and also complexes of these compounds. The term "derivatives" as used in this application is defined as a chemical compound that has undergone a chemical derivation beginning with a compound that acts (active) to change (improve for pharmaceutical use) any of its physicochemical properties, especially so-called prodrugs, for example, their esters and ethers. Examples of well known methods are known to those skilled in the art and can be found for example in Krogsgaard-Larsen et al ., Drugdesign and Discovery Textbook, Taylor & Francis (April 2002). The respective description is incorporated as a reference to this document and is part of the description.
tion.

The purification and isolation of substituted pyrazoline compounds of general formula I of the invention of a corresponding stereoisomer, or salt, or N-oxide, or solvate or any intermediate thereof be carried out, if desired, by conventional methods known to those skilled in the art, for example, methods chromatographic or recrystallization.

The daily dose for humans and animals can vary depending on the factors that are based on the respective species or other factors, such as age, sex, weight or grade of disease among others. The daily dose for humans may be preferably in the range of 1 to 2000, preferably 1 to 1500, more preferably 1 to 1000 milligrams in principle active to be administered in one or several doses per day.

       \ vskip1.000000 \ baselineskip
    

Pharmacological methods I. In vitro determination of affinity for CB1 / CB2 receptors

In-vitro determination of the affinity of the substituted pyrazoline compounds of the invention by the CB1 / CB2 receptors is carried out as described in the publication of Ruth A. Ross, Heather C. Brockie et al ., "Agonist-inverse agonist characterization at CB_ {1} and CB_ {2} cannabinoid receptors of L-759633, L759656 and AM630", British Journal of Pharmacology, 126, 665-672, (1999), in which Transfected human CB 1 and CB 2 receptors from Receptor Biology, Inc. are used. The radioligand used for both receptors is [3 H] -CP55940. The respective parts are incorporated by reference to this document and are part of this description.
tion.

       \ vskip1.000000 \ baselineskip
    

II. In vivo bioassay system to determine cannabinoid activity Mouse tetrad model

It is known that substances with affinity for cannabinoid receptors produce a wide range of effects Pharmacological It is also known that intravenous administration of a substance with affinity for cannabinoid receptors in mice it produces analgesia, hypothermia, sedation and catalepsy. Individually, none of these effects can be considered as proof that a tested substance has an affinity for cannabinoid receptors, since all these effects are common for various kinds of active agents in the nervous system central. However, the substances that show all these effects, that is, the substances that are active in this model called tetrad, they are considered to have affinity for cannabinoid receptors It has also been shown that cannabinoid receptor antagonists are extremely effective in blocking the effects of a cannabinoid agonist in the mouse tetrad model.

The tetrad model is described, for example, in the publication of AC Howlett et al , International Union of Pharmacology XXVII. Classification of Cannabinoid Receptors, Pharmacol Rev 54, 161-202, 2002 and David R. Compton et al ., " In-vivo Characterization of a Specific Cannabinoid Receptor Antagonist (SR141716A): Inhibition of Tetrahydrocannbinol-induced Responses and Apparent Agonist Activity", J. Pharmacol. Exp. Ther. 277, 2, 586-594, 1996. The corresponding parts of the description are incorporated by reference to this document.
ment

       \ vskip1.000000 \ baselineskip
    

Material and methods

In all the following experiments they are used  NMRI male mice weighing 20-30 g (Harlan,  Barcelona, Spain).

Before the tests in the procedures behavioral behaviors then the mice acclimatize to the experimental environment. Control values prior to treatment were determined to measure analgesia using hot plate latency (in seconds), rectal temperature, sedation and catalepsy.

In order to determine agonist activity of the substance to be tested, mice are injected by intravenously the substance to be tested or the vehicle alone. 15 minutes after the injection, the latency of hot plate analgesia. 20 minutes after the injection It measures rectal temperature, sedation and catalepsy.

In order to determine the activity antagonist, the identical procedure is used as for determination of agonist effects, but with the difference of that the substance to be evaluated to determine its activity antagonist is injected 5 minutes before intravenous injection of 1.25 mg / kg of Win-55,212, a known agonist of the cannabinoid receptor.

       \ vskip1.000000 \ baselineskip
    

Hot plate analgesia

Hot plate analgesia is determined according to the method described in Woolfe D. et al . "The evaluation of analgesic action of pethidine hydrochloride (Demerol)", J. Pharmacol. Exp. Ther. 80, 300-307, 1944. The respective description is incorporated as a reference to this document and is part of this description.

The mice are placed on a hot plate (Harvard analgesimeter) at 55 ± 0.5 ° C until they show a painful sensation, licking its legs or jumping, and registers the time for these sensations to occur. This reading is consider as the baseline value (B). The maximum time limit that mice are allowed to remain on the hot plate in absence of any painful response is 40 seconds with the In order to avoid skin lesions. This period is called time. limit (PC).

Fifteen minutes after the administration of the substance to be tested, the mice are placed again on the hot plate and the procedure is repeated above described This period is called post-treatment reading. (PT).

The degree of analgesia is calculated from the formula:

% \ of \ MPE \ of \ analgesia = (PT-B) / (PC-B) \ x \ 100

MPE = maximum possible effect.

       \ vskip1.000000 \ baselineskip
    

Determination of sedation and ataxia

Sedation and ataxia are determined according to the method described in Desmet LKC et al . "Anticonvulsive properties of Cinarizine and Flunarizine in Rats and Mice", Arzneim. -Forsch. (Frug Res) 25, 9, 1975. The respective description is incorporated by reference to this document and forms part of this description.

       \ newpage
    

The scoring system chosen is

0:

no ataxia;

one:

doubtful;

2:

obvious tranquility and silence;

3:

pronounced ataxia;

before, in addition to after treatment.

The percentage of sedation is determined according to the formula:

%\ from\ sedation = mean \ arithmetic / 3 \ X \ 100

       \ vskip1.000000 \ baselineskip
    

Hypothermia

Hypothermia is determined according to the method described in David R. Compton et al . " In-vivo Characterization of a Specific Cannabinoid Antagonist Receptor (SR141716A) Inhibition of Tetrahydrocannbinol-induced Responses and Apparent Agonist Activity", J. Pharmacol Exp Ther. 277, 2, 586-594, 1996. The respective description is incorporated by reference to this document and forms part of this description.

Rectal temperatures are determined initials with a thermometer (Yello Springs Instruments Co., Panlabs) and a thermistor probe inserted 25 mm before the administration of the substance to be tested. Temperature rectal is measured again 20 minutes after administration of the substances to be tested. The temperature difference is calculate for each animal, so that the differences ≥ -2 ° C They are considered to represent activity.

       \ vskip1.000000 \ baselineskip
    

Catalepsy

Catalepsy is determined according to the method described in Alpermann HG et al . "Pharmacological effects of Hoe 249: A new potential antidepressant", Drugs Dev. Res. 25, 267-282. 1992. The respective description is incorporated by reference to this document and forms part of this description.

The cataleptic effect of the substance that is going to be tested is evaluated according to the duration of the catalepsy, putting the animals head down with their legs on top of the wood block.

The scoring system chosen is:

Catalepsy during:

more than 60 seconds = 6; 50 -60 seconds = 5, 40-50 seconds = 4, 30-40 seconds = 3, 20-30 seconds = 2, 5-10 seconds = 1, and less than 5 seconds = 0.

The percentage of catalepsy is determined according to the following formula:

%\ from\ catalepsy = mean \ arithmetic / 6 \ X \ 100

       \ vskip1.000000 \ baselineskip
    

III. In vivo tests to determine activity against obesity a) Acute treatment

Normally treated rats were habituated at a 12/12 h reverse cycle, and the test compound, as well as the saline solution, were orally administered acutely. After administration, cumulative food intake (g) was measured at 6 h and 23 h. After this, the difference in body weight between the control animals and the animals treated with the compound was measured. This is a variation of the test according to Colombo et al . as described below.

       \ vskip1.000000 \ baselineskip
    

b) Long-term treatment

In vivo tests to determine the activity against obesity of the pyrazoline compounds of the invention are carried out as described in the publication of G. Colombo et al ., "Appetite Suppression and Weight Loss after the Cannabinoid Antagonist SR 141716 "; Life Sciences, 63 (8), 113-117, (1998). The respective part of the description is incorporated as a reference to this document and is part of this description.

The present invention is illustrated below. With the help of examples. These illustrations are provided by way of example only and do not limit the general spirit of the present invention

       \ vskip1.000000 \ baselineskip
    

Examples

Example one

N-piperidinyl-5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-1H-pyrazol-3-carboxamide a) Acid 4- (4-chlorophenyl) -2-oxo-3-butenoic

       \ vskip1.000000 \ baselineskip
    

10

       \ vskip1.000000 \ baselineskip
    

They dissolved p-chlorobenzaldehyde (13.3 g, 95 mmol) and pyruvate ethyl (10 g, 86 mmol) in 150 ml of absolute ethanol in a flask of three necks The solution was cooled to 0 ° C and added dropwise. an aqueous solution of NaOH (3.8 g in 45 ml of water) keeping the temperature below or equal to 10 ° C, forming a precipitate yellow-orange color The mixture was stirred reaction for 1 hour at 0 ° C and for another 1.5 hours at temperature ambient (approximately 25 ° C). Then the mixture of reaction was cooled to about 5 ° C and isolated by filtration the insoluble sodium salt of the acid 4- (4-chlorophenyl) -2-oxo-3-butenoic.

The filtrate was left in the refrigerator during night, forming more precipitate that was removed by filtration, it was combined with the first fraction of the salt and washed with diethyl ether. Sodium Salt of Acid 4- (4-chlorophenyl) -2-oxo-3-butenoic it was then treated with a 2n HCl solution, stirred for some minutes and acid separated 4- (4-chlorophenyl) -2-oxo-3-butenoic solid by filtration and dried to give 12.7 g of the product desired (70% of theoretical yield).

IR (KBr, cm -1). 3500-2500, 1719.3, 1686.5, 1603.4, 1587.8, 1081.9.

1 H NMR (CDCl 3, δ): 7.4 (d, J = 8.4 Hz, 2H), 7.5 (d, J = 16.1 Hz, 1H), 7.6 (d, J = 8.4 Hz, 2H), 8.1 (d, J = 16.1 Hz, 1H).

       \ vskip1.000000 \ baselineskip
    

b) acid 5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-pyrazol-3-carboxylic

       \ vskip1.000000 \ baselineskip
    

eleven

       \ vskip1.000000 \ baselineskip
    

Acid mixed 4- (4-chlorophenyl) -2-oxo-3-butenoic  obtained according to step a, (12.6 g, 60 mmol), hydrochloride 2,4-dichlorophenylhydrazine (12.8 g, 60 mmol) and acid glacial acetic acid (200 ml) under a nitrogen atmosphere and it heated to reflux for 4 hours, cooled to temperature ambient (approximately 25 ° C) and poured on ice, obtaining thus a sticky dough that was extracted with methylene chloride. Be washed the combined methylene chloride fractions with water, dried over sodium sulfate, filtered and evaporated to dryness to give a pale yellow solid (12.7 g, 57% of theoretical performance).

IR (KBr, cm -1): 3200-2200, 1668.4, 1458, 1251.4, 1104.8.

1 H NMR (CDCl 3, δ): 3.3 (dd, 1H), 3.7 (dd, 1H), 5.9 (dd, 1H), 7.09-7.25 (m, 7H).

(c) acid chloride 5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-pyrazol-3-carboxylic

       \ vskip1.000000 \ baselineskip
    

       \ vskip1.000000 \ baselineskip
    

       \ vskip1.000000 \ baselineskip
    

12

       \ vskip1.000000 \ baselineskip
    

       \ vskip1.000000 \ baselineskip
    

       \ vskip1.000000 \ baselineskip
    

Acid dissolved 5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-pyrazol-3-carboxylic (2.5 g, 6.8 mmol) obtained according to step (b) in 4 ml of chloride of thionyl under nitrogen atmosphere and heated to reflux during 2.5 hours The excess thionyl chloride was removed from the mixture reaction under reduced pressure and the resulting crude residue (2.6 g) is used without further purification.

IR (KBr, cm -1): 1732.3, 1700, 1533.3, 1478.1, 1212.9, 826, 6.

       \ vskip1.000000 \ baselineskip
    

d) N-piperidinyl-5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydropyrazol-3-carboxamide [this compound is also called acid 5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carboxylic acid piperidin-1-ylamide or 1- (2,4-Dichlorophenyl) -5- (4-chlorophenyl) -4,5-dihydro-N- (piperidin-1-yl) -1H-pyrazol-3-carboxamide]

       \ vskip1.000000 \ baselineskip
    

       \ vskip1.000000 \ baselineskip
    

       \ vskip1.000000 \ baselineskip
    

13

       \ vskip1.000000 \ baselineskip
    

       \ vskip1.000000 \ baselineskip
    

       \ vskip1.000000 \ baselineskip
    

N-aminopiperidine (0.6 ml, 5.6 mmol) and triethylamine (4 ml) were dissolved in methylene chloride (25 ml) under a nitrogen atmosphere. The resulting mixture was cooled on ice to 0 ° C and a solution of 5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-pyrazol-3-carboxylic acid chloride was added dropwise obtained in step (c) in methylene chloride (15 ml). The resulting reaction mixture was stirred at room temperature (approximately 25 ° C) overnight. The reaction mixture was washed with water, followed by a saturated aqueous solution and again with water, dried over sodium sulfate, filtered and evaporated to dryness on a rotary evaporator. The resulting crude solid was crystallized from ethanol. The crystallized solid was removed by filtration and the mother liquor was concentrated to give a second fraction of crystallized product. The two fractions were combined to give a total amount of 1.7 g (57% of theoretical yield) of the title compound having a melting point of 183-
186 ° C.

IR (KBr, cm -1) 3222.9, 2934.9, 1647.4, 1474.7, 1268.3, 815.6.

1 H NMR (CDCl 3, δ): 1.4 (m, 2H), 1.7 (m, 4H), 2.8 (m, 4H), 3.3 (dd, J = 6.1 and 18.3 Hz, 1H), 3.7 (dd, J = 12.5 and 18.3 Hz, 1H), 5.7 (dd, J = 6.1 and 12.5 Hz, 1H), 7.0-7.2 (m, 6H), 7.4 (s, 1H).

The compounds according to the examples 2-6 following have been prepared analogously to process described in example 1.

       \ vskip1.000000 \ baselineskip
    

Example 2

[1,2,4] triazol-4-yl amide of the acid 5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carboxylic acid

Melting point: 134-138 ° C.

IR (KBr, cm -1): 3448, 1686, 1477, 1243, 1091, 821.

1 H NMR (CDCl 3, δ): 3.1 (dd, J = 6.2 and 17.9 Hz, 1H), 3.7 (dd, J = 12.3 and 17.9 Hz, 1H), 5.9 (dd, J = 6.2 and 12.3 Hz, 1H), 7.2-7.5 (m, 7H), 8.7 (s, 2H), 12.0 (sa, 1 H).

       \ vskip1.000000 \ baselineskip
    

Example 3

Hydrochloride (4-methyl-piperazin-1-yl) -amide of the acid 5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carboxylic acid

Melting point: 150-155 ° C.

IR (KBr, cm -1): 3433, 1685, 1477, 1296, 1246, 1088, 1014, 825.

1 H NMR (CDCl 3, δ): 2.7 (d, J = 4.2 Hz, 3H), 3.0-3.4 (m, 9H), 3.6 (dd, J = 11.9 and 17.9 Hz, 1H), 5.8 (dd, J = 5.5 and 11.9 Hz, 1H), 7.1 (d, J = 8.4 Hz, 2H), 7.25 (2d, J = 8.4 and 8.7 Hz, 3H), 7.4 (d, J = 2.2 Hz, 1H), 7.5 (d, J = 8.7 Hz, 1H), 9.8 (s, 1H), 11.2 (sa).

       \ vskip1.000000 \ baselineskip
    

Example 4

Acid diethylamide 5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carboxylic acid

This compound was obtained in the form of a oil.

IR (film, cm -1): 2974, 1621, 1471, 1274, 1092, 820.

1 H NMR (CDCl 3, δ): 1.2 (m, 6H), 3.3-3.9 (m, 6H), 5.6 (dd, J = 5.8 and 11.7 Hz, 1H), 7-7.25 (m, 7H).

       \ vskip1.000000 \ baselineskip
    

Example 5

[5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1H-pyrazol-3-yl] -piperidin-1-yl-methanone

Melting point: 105-110 ° C.

IR (KBr, cm -1): 2934, 1622, 1470, 1446, 1266, 1010, 817.

1 H NMR (CDCl 3, δ): 1.7 (m, 6H), 3.4 (dd, J = 5.7 and 17.9 Hz, 1H), 3.7 (m, 3H), 3.9 (m, 2H), 5.6 (dd, J = 6.1 and 11.9 Hz, 1H), 7-7.25 (m, 7H).

       \ vskip1.000000 \ baselineskip
    

Example 6

N- [5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1H-pyrazol-3-carbonyl] -4-methyl-phenylsulfonamide

This compound was obtained as a solid. amorphous.

IR (KBr, cm -1): 1697, 1481, 1436, 1340, 1169, 1074, 853.

1 H NMR (CDCl 3, δ): 2.4 (s, 3H), 3.2 (dd, J = 6.6 and 18.3 Hz, 1H), 3.6 (dd, J = 12.8 and 18.3 Hz, 1H), 5.8 (dd, J = 6.6 and 12.8 Hz, 1H), 7 (d, J = 8.2 Hz, 2H), 7.2 (s, 1H), 7.3-7.4 (m, 6H), 8 (d, J = 8.1 Hz, 2H), 9 (s, 1 HOUR).

       \ newpage
    

Example 7

N-oxide N-piperidinyl-5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydropyrazol-3-carboxamide

N-Piperidinyl-5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydropyrazol-3-carboxamide (0.15 g, 332) was dissolved
mmol) in 7 ml of dichloromethane in an inert atmosphere of nitrogen gas. The resulting solution was cooled on ice to 0 ° C and m-chloroperbenzoic acid (0.204 g, 0.83 mmol) was added in several portions. After stirring for 15 minutes a control performed by thin layer chromatography showed that no starting material remained. A saturated solution of sodium bicarbonate was then added slowly, the organic phase was separated, washed with water, dried over sodium sulfate and filtered. The filtered solution was evaporated to dryness and the crude product was purified through column chromatography to give 78 mg (50% of theory) of N-piperidinyl-5- (4-chlorophenyl) -1- ( 2,4-Dichlorophenyl) -4,5-dihydropyrazol-3-carboxamide in the form of a white solid having a melting point of 115-120 ° C.

IR (KBr, cm -1): 3202, 1678, 1654, 1474, 1309, 1107.

1 H-NMR (CDCl 3, δ): 1.6 (m, 2H), 1.8-2.0 (m, 4H), 2.55 (m, 2H), 3.3 (dd, J = 6.3 Hz and 18.2 Hz, 1H), 3.7 (m, 3H), 5.8 (dd, J = 6.3 Hz and 12.5 Hz, 1H), 7.0-7.3 (m, 7H), 8.5 (s, 1 HOUR).

       \ vskip1.000000 \ baselineskip
    

Example 8

10 mg tablets

They mixed intensely N-piperidinyl-5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydropyrazol-3-carboxamide (10 mg), corn starch (50 mg), lactose monohydrate of 200 granule size (130 mg), hydroxypropyl methyl cellulose 6 cP (6 mg) and cross-linked sodium carboxymethyl cellulose (10 mg), and granulated with sodium lauryl sulfate (1 mg) and purified QS water. He  resulting granulate was compressed with magnesium stearate, giving a 220 mg tablet, using a conventional press of compress.

       \ vskip1.000000 \ baselineskip
    

Pharmacological data I. In vitro determination of affinity to CB1 / CB2 receptors

The affinity of pyrazoline compounds Substitutes of the invention were determined as described previously. Some of the values obtained are given in the following table I:

       \ vskip1.000000 \ baselineskip
    

       \ vskip1.000000 \ baselineskip
    

TABLE I

14

       \ vskip1.000000 \ baselineskip
    

       \ vskip1.000000 \ baselineskip
    

As can be seen from the values given in the Table 1, the pyrazoline compounds of the invention are suitable particularly to regulate the CB1 receptor.

       \ vskip1.000000 \ baselineskip
    

II. In vivo bioassay system for the determination of cannabinoid activity

The determination of cannabinoid activity in vivo was determined as described above. Some of the values obtained are given in the following table II:

       \ vskip1.000000 \ baselineskip
    

TABLE II

fifteen

i.v. intravenous TO: Proof of plate hot B: Hypothermia C: Catalepsy D: Sedation

       \ vskip1.000000 \ baselineskip
    

As can be seen from the values given in the  Table II, the pyrazoline compounds of the invention show a antagonistic effect

Claims (14)

1. Use of at least one pyrazoline compound substituted of general formula I,

         \ vskip1.000000 \ baselineskip
      

         \ vskip1.000000 \ baselineskip
      

         \ vskip1.000000 \ baselineskip
      

         \ vskip1.000000 \ baselineskip
      

16

         \ vskip1.000000 \ baselineskip
      

         \ vskip1.000000 \ baselineskip
      

         \ vskip1.000000 \ baselineskip
      

in the that

quad

R 1 represents a phenyl group optionally at less monosubstituted;

quad

R2 represents a phenyl group optionally at less monosubstituted;

quad

R 3 represents a saturated cycloaliphatic group or unsaturated, optionally at least monosubstituted, containing optionally at least one heteroatom as a ring member, which it can be condensed with a cyclic, mono or polycyclic system, optionally at least monosubstituted, or R3 represents a optionally at least monosubstituted aryl or heteroaryl group, which may be condensed with a cyclic, mono or polycyclic, optionally at least monosubstituted, or R3 represents a moiety -NR 4 R 5;

quad

R 4 and R 5, identical or different, they represent a hydrogen atom, an aliphatic radical, not branched or branched, saturated or unsaturated, optionally at less monosubstituted, a saturated or unsaturated cycloaliphatic group, optionally at least monosubstituted, which optionally contains at least one heteroatom as a ring member, which may be condensed with a cyclic, mono or polycyclic system, optionally at least monosubstituted, or an aryl group or optionally at least monosubstituted heteroaryl, which may be condensed with a cyclic, mono or polycyclic system, optionally at least monosubstituted and / or linked through a linear or branched alkylene group, a moiety -SO 2 -R 6, or a moiety -NR 7 R 8; with the condition that R 4 and R 5 do not represent identical to hydrogen;

quad

R 6 represents an aliphatic, linear or branched, saturated or unsaturated, optionally at least monosubstituted, a saturated or unsaturated cycloaliphatic group, optionally at least monosubstituted, which optionally contains at least one heteroatom as a ring member, which may be condensed with a cyclic, mono or polycyclic system, or a group aryl or heteroaryl optionally at least monosubstituted, which can be condensed with a cyclic, mono or polycyclic system and / or linked through a linear akylene group or branched;

quad

R 7 and R 8, identical or different, they represent a hydrogen atom, an aliphatic radical, not branched or branched, saturated or unsaturated, optionally at less monosubstituted, a saturated cycloaliphatic group or unsaturated, optionally at least monosubstituted, containing optionally at least one heteroatom as a ring member, which it can be condensed with a cyclic, mono or polycyclic system, optionally at least monosubstituted, or an aryl group or optionally at least monosubstituted heteroaryl, which may be condensed with a cyclic, mono or polycyclic system, optionally at least monosubstituted and / or linked through an alkylene group linear or branched;

quad

optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any mixing ratio, or a corresponding N-oxide of the themselves, or a corresponding salt thereof, or a solvate corresponding thereof; and optionally one or more pharmaceutically acceptable excipients,

quad

for the manufacture of a medicine for Metabolic syndrome treatment.

2. Use according to claim 1, characterized in that R 1 represents a phenyl group which is optionally substituted by one or more substituents independently selected from the group consisting of a linear or branched C 1-6 alkyl group, a group linear or branched C 1-6 alkoxy, a halogen atom, CH 2 F, CHF 2, CF 3, CN, OH, NO 2, - (C = O) -R ', SH, SR ', SOR', SO2R ', NH2, NHR', NR'R '', - (C = O) -NH_2, - (C = O) -NHR ' and - (C = O) -NR'R '' in which R 'and R''independently represents linear or branched C 1-6 alkyl for each substituent, preferably R 1 represents a phenyl group which is optionally substituted by one or more substituents selected from the group consisting of methyl, ethyl, F, Cl, Br and CF 3, more preferably R 1 represents a phenyl group that is monosubstituted with a chlorine atom in the position 4. 3. Use according to claim 1 or 2, characterized in that R2 represents a phenyl group which is optionally substituted by one or more substituents independently selected from the group consisting of a linear or branched C1-6 alkyl group, a linear or branched C 1-6 alkoxy group, a halogen atom, CH 2 F, CHF 2, CF 3, CN, OH, NO 2, - (C = O) -R ', SH, SR', SOR ', SO2R', NH2, NHR ', NR'R'', - (C = O) -NH_2, - (C = O) - NHR 'and - (C = O) -NR'R'', in which R' and optionally R '' independently represents linear or branched C 1-6 alkyl for each substituent, preferably R2 represents a phenyl group that is optionally substituted by one or more substituents independently selected from the group consisting of methyl, ethyl, F, Cl, Br and CF 3, more preferably R2 represents a phenyl group that is disubstituted with two halogen atoms, preferably chlorine atoms, in their 2 and 4 position. 4. Use according to one or more of claims 1-3, characterized in that R 3 represents a C 3-8 cycloaliphatic group, saturated or unsaturated, optionally at least monosubstituted, optionally containing at least one heteroatom as a member ring, which may be condensed with a cyclic, mono or polycyclic system, optionally at least monosubstituted, or R3 represents a 5 or 6 membered aryl or heteroaryl group, optionally at least monosubstituted, which may be condensed with a cyclic, mono or polycyclic system, optionally at least monosubstituted, or R 3 represents a moiety -NR 4 R 5, preferably R 3 represents a saturated C 3-8 cycloaliphatic group , optionally at least monosubstituted, optionally containing one or more nitrogen atoms as ring members, which may be condensed with a cyclic, mono or polycyclic system, optionally at least monosubstituted, or R3 represents a -NR ^ moiety {4 R5, more pref errably R 3 represents a pyrrolidinyl group, a piperidinyl group or a piperazinyl group, in which each of these groups can be substituted with one or more C 1-6 alkyl groups, or R 3 represents a moiety -NR 4 R 5. 5. Use according to one or more of claims 1-4, characterized in that R 4 and R 5, identical or different, represent a hydrogen atom, C 1-6 aliphatic radical, unbranched or branched, saturated or unsaturated, optionally at least monosubstituted, a saturated C 3-8 cycloaliphatic group, optionally at least monosubstituted, optionally containing at least one or more nitrogen atoms as ring members, which may be condensed with a system cyclic, mono or polycyclic, optionally at least monosubstituted, or a 5 or 6 membered aryl or heteroaryl group, optionally at least monosubstituted, which may be condensed with a cyclic, mono or polycyclic system, optionally at least monosubstituted and / or attached to through a methylene (-CH2 -) or ethylene (-CH2 -CH2) - group, a -SO2 -R6 moiety, or a -NR ^ moiety 7 R 8, preferably one of these residues R 4 and R 5 represents a hydrogen atom and the other of these resi duos R 4 and R 5 represents a C 3-8 cycloaliphatic group, saturated or unsaturated, optionally at least monosubstituted, optionally containing at least one heteroatom as a ring member, which may be condensed with a cyclic, mono or polycyclic system, optionally at least monosubstituted, or a 5 or 6 membered aryl or heteroaryl group, optionally at least monosubstituted, which may be condensed with a cyclic, mono or polycyclic system, optionally at least monosubstituted, a moiety - SO 2 -R 6, or a moiety -NR 7 R 8, or R 4 and R 5, identical or different, each represents a C_ alkyl group {1-6, more preferably one of the residues R 4 and R 5 represents a hydrogen atom and the other of these residues R 4 and R 5 represents an optionally pyrrolidinyl group at least monosubstituted, an optionally at least monosubstituted piperidinyl group, an optionally at least monosubstituted piperazinyl group, a triazolyl group optionally at least monosubstituted, a moiety -SO2 -R6, or a moiety -NR7R8, or R4 and R5, identical or different , represent a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, a sec-butyl group or a tert-group
butyl. 6. Use according to one or more of claims 1-5, characterized in that R 6 represents a C 1-6 aliphatic group, linear or branched, saturated or unsaturated, optionally at least monosubstituted, a saturated cycloaliphatic group or unsaturated, optionally at least monosubstituted, optionally containing at least one heteroatom as a ring member, which may be condensed with a cyclic, mono or polycyclic system, or an aryl or heteroaryl group of 5 or 6 members, optionally at least monosubstituted, which may be condensed with a cyclic, mono or polycyclic system and / or linked through a methylene (-CH2-) or ethylene (-CH2 -CH2) - group, preferably R <2> 6} represents a C 1-6 alkyl group, a saturated cycloaliphatic group, optionally at least monosubstituted, which may be condensed with a cyclic, mono or polycyclic system, or a phenyl group, which is optionally substituted with one or more groups C 1-6 alkyl.

         \ newpage
      

7. Use according to one or more of claims 1-6, characterized in that R 7 and R 8, identical or different, represent a hydrogen atom, a C 1-6 aliphatic radical, unbranched or branched, saturated or unsaturated, optionally at least monosubstituted, a C 3-8 cycloaliphatic group, saturated or unsaturated, optionally at least monosubstituted, optionally containing at least one heteroatom as a ring member, which may be condensed with a system cyclic, mono or polycyclic, optionally at least monosubstituted, or a 5 or 6 membered aryl or heteroaryl group, optionally at least monosubstituted, which may be condensed with a cyclic, mono or polycyclic system, optionally at least monosubstituted and / or linked to through a methylene (-CH2 -) or ethylene group
(-CH 2 -CH 2) -, preferably R 7 and R 8, identical or different represent a hydrogen atom or an alkyl radical
C_ {1-6}. 8. Use according to one or more of claims 1-7, characterized in that in the general formula I

quad

R 1 represents a phenyl group that is optionally substituted by one or more selected substituents regardless of the group consisting of methyl, ethyl, F, Cl, Br and CF 3,

quad

R2 represents a phenyl group that is optionally substituted by one or more selected substituents regardless of the group consisting of methyl, ethyl, F, Cl, Br and CF 3,

quad

R 3 represents a pyrrolidinyl group, a group piperidinyl or a piperazinyl group, in which each of those groups may be substituted with one or more alkyl groups C 1-6, or R 3 represents a moiety -NR 4 R 5 -,

quad

one of the residues R 4 and R 5 represents a hydrogen atom and the other of these residues R 4 and R 5 represents a pyrrolidinyl group optionally at least monosubstituted; a piperidinyl group optionally at least monosubstituted; a piperazinyl group optionally at least monosubstituted; a triazolyl group optionally at least monosubstituted; a moiety -SO 2 -R 6 -; or a remainder -NR 7 R 8 -, or R 4 and R 5, identical or different, they represent a methyl group, an ethyl group, a group n-propyl, an isopropyl group, a group n-butyl, a sec-butyl group or a tert-butyl group,

quad

R 6 represents an alkyl group C 1-6; a cycloaliphatic group, saturated, optionally at least monosubstituted, which may be condensed with a cyclic, monocyclic or polycyclic system; or a group phenyl that is optionally substituted with one or more groups C 1-6 alkyl, and

quad

R 7 and R 8, identical or different, represent a hydrogen atom or an alkyl radical C_ {1-6}.

9. Use according to one or more of claims 1-8, characterized in that in the general formula I

quad

R 1 represents a phenyl group that is optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of alkyl C 1-6 linear or branched, alkoxy C 1-6 linear or branched, F, Cl, Br, I, CH 2 F, CHF 2, CF 3, CN, OH, NO 2, - (C = O) -R ', SH, SR', SOR ', SO_2R', NH_ {2}, NHR ', NR'R' ', - (C = O) -NH2, - (C = O) -NHR 'and - (C = O) -NR'R' ', in the that R 'and R' 'each time they appear represent independent a linear C 1-6 alkyl group or branched,

quad

R2 represents a phenyl group that is optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of alkyl C 1-6 linear or branched, alkoxy C 1-6 linear or branched, F, Cl, Br, I, CH 2 F, CHF 2, CF 3, CN, OH, NO 2, - (C = O) -R ', SH, SR', SOR ', SO_2R', NH_ {2}, NHR ', NR'R' ', - (C = O) -NH2, - (C = O) -NHR 'and - (C = O) -NR'R' ', in the that R 'and R' 'each time they appear represent independent a linear C 1-6 alkyl group or branched,

quad

R 3 represents a cycloaliphatic group C_ {3-8} saturated or unsaturated, in which said C 3-8 cycloaliphatic group is substituted optionally with 1, 2, 3 or 4 substituents selected regardless of the group consisting of alkyl C 1-6 linear or branched, alkoxy C 1-6 linear or branched, OH, F, Cl, Br, I, CN, CH 2 F, CHF 2, CF 3 and oxo (= O) and in which said C 3-8 cycloaliphatic group may contain 1, 2 or  3 heteroatoms independently selected from the group that consists of N, O and S as members of the ring, or R3 represents a moiety -NR 4 R 5 -,

quad

R 4 represents a hydrogen atom or a group linear or branched C 1-6 alkyl,

quad

R 5 represents an alkyl group C 1-6 linear or branched; a rest -SO 2 -R 6 -; a cycloaliphatic group C_ {3-8} saturated or unsaturated, in which said C 3-8 cycloaliphatic group is substituted optionally with 1, 2, 3 or 4 substituents selected regardless of the group consisting of alkyl group C 1-6 linear or branched, an alkoxy group C 1-6 linear or branched, OH, F, Cl, Br, I, CN CH 2 F, CHF 2, CF 3 and oxo (= O) and in which said group C 3-8 cycloaliphatic may contain 1, 2 or 3 heteroatoms independently selected from the group that consists of N, O and S as members of the ring, and

quad

R 6 represents a phenyl group that is optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of a group linear or branched C 1-6 alkyl, a group linear or branched C 1-6 alkoxy, F, Cl, Br, I, CH 2 F, CHF 2, CF 3, CN, OH, NO 2, - (C = O) -R ', SH, SR', SOR ', SO_2R', NH_ {2}, NHR ', NR'R' ', - (C = O) -NH2, - (C = O) -NHR 'and - (C = O) -NR'R' ', in the that R 'and R' 'each time they appear represent independent a linear C 1-6 alkyl group or branched.

10. Use according to one or more of claims 1-9, characterized in that in the general formula I

quad

R 1 represents a phenyl group that is optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of methyl, ethyl, F, Cl, Br and CF 3,

quad

R2 represents a phenyl group that is optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of methyl, ethyl, F, Cl, Br and CF 3,

quad

R 3 represents a pyrrolidinyl group, a group piperidinyl or a piperazinyl group, in which each of those groups may be substituted with one or more alkyl groups C 1-6, or R 3 represents a moiety -NR 4 R 5 -,

quad

R 4 represents a hydrogen atom or a group linear or branched C 1-6 alkyl,

quad

R 5 represents an alkyl group C 1-6 linear or branched; a rest -SO 2 -R 6 -; a pyrrolidinyl group; a piperidinyl group; a piperazinyl group; a group homo-piperazinyl; a morpholinyl group; a group triazolyl; in which each of the heterocyclic rings can be substituted with one or more alkyl groups C_ {1-6}, identical or different, and

quad

R 6 represents a phenyl group that is optionally substituted with one or more alkyl groups C_ {1-6}, which can be identical or different.

11. Use according to one or more of claims 1-10, characterized in that in the general formula I

quad

R 1 represents a phenyl ring, which is monosubstituted with a halogen atom, preferably an atom of chlorine, in position 4,

quad

R2 represents a phenyl ring, which is disubstituted with two halogen atoms, preferably atoms of chlorine, in its position 2 and 4,

quad

R 3 represents a pyrrolidinyl group, a group piperidinyl, a piperazinyl group, a group homo-piperazinyl, a morpholinyl group, or a moiety -NR 4 R 5 -,

quad

R 4 represents a hydrogen atom or a group linear or branched C 1-6 alkyl,

quad

R 5 represents an alkyl group C 1-6 linear or branched; a rest -SO 2 -R 6 -; a pyrrolidinyl group; a piperidinyl group; a piperazinyl group; a group homo-piperazinyl; a morpholinyl group; or a group triazolyl in which each of the heterocyclic rings can be substituted with one or more alkyl groups C_ {1-6}, identical or different, and

quad

R 6 represents a phenyl group that is optionally substituted with one or more alkyl groups C_ {1-6}, which can be identical or different.

12. Use according to one or more of claims 1 to 11, characterized in that the pyrazoline compound is selected from the group consisting of

quad

N-piperidinyl-5- (4-chloro-phenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-1H-pyrazol-3-carboxamide,

quad

[1,2,4] -triazol-4-yl-amide of the acid 5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carboxylic acid,

quad

(4-methyl-piperazin-1-yl) -amide of the acid 5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carboxylic acid,

quad

acid diethylamide 5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carboxylic acid,

quad

[5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-yl] -piperidine-1-yl-methanone Y

quad

N- [5- (4-Chloro-phenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -4-methylphenylsulfonamide,

quad

optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any mixing ratio, or a corresponding N-oxide of the themselves, or a corresponding salt thereof, or a solvate corresponding thereof.

         \ newpage
      

13. Use according to one or more of claims 1 to 12, characterized in that the pyrazoline compound is one of the following compounds:

         \ vskip1.000000 \ baselineskip
      

17

         \ vskip1.000000 \ baselineskip
      

in each case optionally fit of a corresponding N-oxide, a corresponding salt, or a corresponding solvate of the same. 14. Use according to one or more of the claims 1-13, in which the medication is for administration once a day, twice a day, or three times a day, preferably once a day, or twice a day, more preferably once a day.